Healthcare Industry News: Bronchiectasis
News Release - June 5, 2007
Aradigm Names D. Jeffery Grimes as General Counsel and Corporate SecretaryHAYWARD, CA--(Healthcare Sales & Marketing Network)--Jun 5, 2007 -- Aradigm Corporation (the "Company") (OTC BB:ARDM.OB ) announced today that it has named D. Jeffery Grimes as General Counsel and Corporate Secretary, effective June 18, 2007. Mr. Grimes will report to Igor Gonda, Ph.D., Aradigm's President and Chief Executive Officer.
"We are very pleased to have Jeffery Grimes join our organization. His in-depth knowledge of the healthcare industry and broad commercial and regulatory experience with public companies will be important as we transition to a specialty pharmaceutical business model," said Dr. Gonda.
Prior to joining Aradigm, Mr. Grimes served as an attorney in the Trademarks & Brands Group at Intel Corporation. Earlier, he served as Assistant General Counsel at Connectics Corporation, a publicly traded specialty pharmaceutical company, where he was primarily responsible for supporting the Sales, Marketing, Clinical and Regulatory departments. Previously, Mr. Grimes was Vice President, Corporate Counsel & Secretary for GN ReSound and Beltone Electronics Corporation. Prior to that he was Corporate Counsel at National Information Group. Mr. Grimes received a J.D. from the University of Colorado School of Law, an M.B.A. from the University of Colorado School of Graduate Business Administration, and a B.S. from the University of Colorado at Boulder.
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, Bronchiectasis, pulmonary hypertension, asthma, inhalation anthrax infections and smoking cessation.
In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. Novo Nordisk also remains a substantial shareholder and investor in Aradigm. More information about Aradigm can be found at www.aradigm.com.
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including changes to our business model, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.
Aradigm and AERx are registered trademarks of Aradigm.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.